Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 676 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Morning Group Clear all
Completed Not applicable Interventional Results available

Outpatient Foley For Starting Induction of Labor at TErm

NCT02756689
View directory record Official record
Conditions
Pregnancy
Interventions
Inpatient cervical ripening, Outpatient cervical ripening
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Female only
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Oct 22, 2026, 2:42 AM EDT
Recruiting Phase 2 Interventional

Boosting Olfactory and Sensory Training Study (BOOST)

NCT07221123
View directory record Official record
Conditions
HIV (Human Immunodeficiency Virus)
Interventions
Conventional Smell Training Group, Scented Marker Group
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 22, 2026, 2:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sleep and Social Experiences Study 2

NCT05166590
View directory record Official record
Conditions
Sleep, Blood Pressure
Interventions
Sleep Restriction
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 64 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 22, 2026, 2:42 AM EDT
Recruiting Not applicable Interventional

Optimization of Postoperative Bowel Habits

NCT06335797
View directory record Official record
Conditions
Constipation
Interventions
Senna Tab, Dulcolax Suppositories
Dietary Supplement
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 22, 2026, 2:42 AM EDT
Completed Not applicable Interventional Results available

Personalized Integrated Chronotherapy for Perinatal Depression

NCT04364646
View directory record Official record
Conditions
Depression, Postpartum Depression, Prenatal Disorder, Circadian Dysregulation, Pregnancy Related, Sleep Disturbance
Interventions
Personalized Integrated Chronotherapy
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Glen Oaks, New York • Chapel Hill, North Carolina • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 22, 2026, 2:42 AM EDT
Completed Phase 2 Interventional Results available

Ketoconazole and Dexamethasone in Prostate Cancer

NCT01036594
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ketoconazole, Hydrocortisone, Dexamethasone
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Oct 22, 2026, 2:42 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Ketone Conferred Resiliency Against Sleep Restriction With Nutritional Intervention.

NCT06075914
View directory record Official record
Conditions
Sleep Deprivation, Nutritional Intervention
Interventions
Ketogenic Intervention, Mediterranean Intervention, Placebo, Ketone Ester
Other · Dietary Supplement
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 40 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 22, 2026, 2:42 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01706328
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF/VI 100/25 Inhalation Powder NDPI, Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS, Placebo Inhalation Powder NDPI, Placebo Inhalation Powder ACCUHALER/DISKUS, Salbutamol as needed
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
16
States / cities
Clearwater, Florida • DeLand, Florida • Coeur d'Alene, Idaho + 13 more
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Oct 22, 2026, 2:42 AM EDT
Completed Phase 3 Interventional Results available

Low Dose Oral Methotrexate in Pediatric Crohn's Disease Patients Initiating Anti-Tumor Necrosis Factor (Anti-TNF) Therapy

NCT02772965
View directory record Official record
Conditions
Pediatric Crohn's Disease
Interventions
Methotrexate, Sugar pill (placebo)
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Up to 20 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
32
States / cities
Birmingham, Alabama • Alto, California • New Haven, Connecticut + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 22, 2026, 2:42 AM EDT
Completed No phase listed Observational

A Cross-Functional, Population-Representative, Web-Based, Epidemiologic Study to Estimate the Prevalence and Burden of Nocturia Due to Nocturnal Polyuria in the US

NCT04125186
View directory record Official record
Conditions
Nocturnal Polyuria
Interventions
Baseline EpiNP survey, Bladder diary, Testing of EpiNP baseline survey, bladder diary and a qualitative interview, No other intervention
Diagnostic Test · Other
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
10,190 participants
Timeline
2019 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Oct 22, 2026, 2:42 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Trial for Alcohol Use Disorder and Post Traumatic Stress Disorder (PTSD)

NCT02966873
View directory record Official record
Conditions
Post Traumatic Stress Disorder (PTSD), Addiction, Alcohol Abuse
Interventions
N-Acetylcysteine (NAC) Treatment, Cognitive Behavioral Therapy (CBT), Inactive Placebo Oral Capsule, Functional magnetic resonance imaging (fMRI), Proton magnetic resonance spectroscopy (MRS) Imaging
Drug · Behavioral · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
182 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
2
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 22, 2026, 2:42 AM EDT
Completed Not applicable Interventional Results available

Technology-Supported Physical Activity Intervention for Metastatic Breast Cancer Survivors: Fit2ThriveMB

NCT04129346
View directory record Official record
Conditions
Metastatic Breast Cancer, Obesity
Interventions
Fit2ThriveMB App, Fitbit, Physical Activity Coaching Calls, Healthy Living Coaching Calls, Cancer.net app
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 10, 2022 · Synced Oct 22, 2026, 2:42 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Effect of Ticagrelor in Reducing the Number of Days With Pain in Patients With Sickle Cell Disease

NCT02482298
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Ticagrelor, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 30 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Miami, Florida • Bethesda, Maryland • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 22, 2026, 2:42 AM EDT
Withdrawn Phase 2 Interventional

Use of Kudzu Extract in the Study of Its Ability to Reduce Alcohol Drinking in Treatment Seeking Alcohol Dependent Persons

NCT01853293
View directory record Official record
Conditions
Alcohol Abuse, Alcohol Dependence, Heavy Drinking Days
Interventions
Kudzu extract, Placebo, Medical Management
Drug · Behavioral
Lead sponsor
Mclean Hospital
Other
Eligibility
21 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2015 · Synced Oct 22, 2026, 2:42 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes

NCT00622284
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo identical to BI 1356 5mg, Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg, BI 1356, Glimepiride
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
23
States / cities
Tempe, Arizona • Chula Vista, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2014 · Synced Oct 22, 2026, 2:42 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

A Clinical Trial to Evaluate the Effects of a Herbal Tincture on Energy Levels, Weight Management, and Markers of Metabolic Health

NCT06949540
View directory record Official record
Conditions
Stress, Fatigue
Interventions
Blue Burn Tincture
Dietary Supplement
Lead sponsor
Apothekary
Industry
Eligibility
30 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 22, 2026, 2:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Dolutegravir on Metformin Pharmacokinetics in Healthy Adult Subjects

NCT02064374
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Metformin 500 mg q12h, Dolutegravir 50 mg q24h, Dolutegravir 50 mg q12h
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 26, 2014 · Synced Oct 22, 2026, 2:42 AM EDT
Completed Phase 4 Interventional Results available

Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population

NCT02038790
View directory record Official record
Conditions
Opioid Dependence
Interventions
Suboxone Sublingual Film, Zubsolv sublingual tablets
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 22, 2026, 2:42 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation

NCT02516410
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-661 plus ivacaftor combination, Ivacaftor, Placebo (matched to VX-661 plus ivacaftor combination), Placebo (matched to ivacaftor)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
22
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Oct 22, 2026, 2:42 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02164513
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
fluticasone furoate (FF), vilanterol (VI), umeclidinium bromide (UMEC)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
10,355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
269
States / cities
Athens, Alabama • Birmingham, Alabama • Florence, Alabama + 226 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Oct 22, 2026, 2:42 AM EDT
Completed Phase 2 Interventional Results available

Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD

NCT01210560
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
Tolvaptan MR, Tolvaptan IR
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
6
States / cities
Boston, Massachusetts • Minneapolis, Minnesota • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 22, 2026, 2:42 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effectiveness of Modafinil and D-amphetamine in Treating Cocaine Dependent Individuals

NCT00218062
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
D-Amphetamine 30mg, D-Amphetamine 60mg, Modafinil 200mg, Modafinil 400mg, Therapy, Placebo
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2017 · Synced Oct 22, 2026, 2:42 AM EDT
Completed Phase 2 Interventional

Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients

NCT01941836
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
ETC-1002, Ezetimibe
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
68
States / cities
Birmingham, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2019 · Synced Oct 22, 2026, 2:42 AM EDT
Not yet recruiting Not applicable Interventional

Virtual Lifestyle Medicine Group Visits for High Blood Pressure

NCT07698509
View directory record Official record
Conditions
Hypertension
Interventions
Lifestyle Medicine Virtual group, Usual Care Group
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 22, 2026, 2:42 AM EDT